Table 4.
Effect of pooled sensitivity and specificity of fecal calprotectin on patients.
| Test Result | Number of Participants (Studies) | Number of Results per 100 Patients Tested (95% CI) | Importance (Grade) * |
Comments | ||
|---|---|---|---|---|---|---|
| Prevalence 25% | Prevalence 50% | Prevalence 75% | ||||
| True positive (TP) |
2457 (24) |
18 (13 to 21) | 36 (26 to 43) | 54 (40 to 64) | 8 | Benefit from early identification of relapse. |
| False negative (FN) |
7 (4 to 12) | 14 (7 to 24) | 21 (11 to 35) | 9 | Detriment from delays in identification of relapse and treatment. | |
| True negative (TN) |
56 (46 to 63) | 37 (31 to 42) | 19 (15 to 21) | 8 | Benefit from reassurance and relief of economic costs. | |
| False positive (FP) |
19 (12 to 29) | 13 (8 to 19) | 6 (4 to 10) | 7 | Detriment from undertake unnecessary psychological burden and financial expenditure. | |
CI: Confidence interval. * GRADE recommends classifying patient-important outcomes on a 9-point scale: 7–9: critical for decision making; 4–6: essential but not critical for decision making; and 1–3: of lower importance to patients.